盐酸缬更昔洛韦片的效果好吗？

The prodrug of ganciclovir is rapidly converted into ganciclovir after oral administration, reducing toxicity. Ganciclovir, trade name Vansevir, etc., is an antiviral drug used to treat patients with acquired immunodeficiency syndrome (AIDS) combined with cytomegalovirus (CMV) retinitis, and to prevent CMV infection in high-risk solid organ transplant patients. Are Valganciclovir Hydrochloride Tablets effective?

Clinical studies of valganciclovir in AIDS patients infected with CMV retinitis have shown that valganciclovir hydrochloride tablets and intravenous ganciclovir are equally effective in the induction treatment of CMV retinitis. In the study, patients with newly diagnosed CMV retinitis were randomly assigned to the valganciclovir hydrochloride tablet group or the intravenous ganciclovir group for induction therapy. The proportion of patients with progression of CMV retinitis at week 4 was the same in both groups.

After induction therapy, both groups of patients in this study continued to receive maintenance therapy with valganciclovir hydrochloride tablets 900 mg daily. The mean (median) time from randomization to progression of CMV retinitis was 226 (160) days and 219 (125) days in patients who received Vancevir or intravenous ganciclovir followed by maintenance therapy with Vancevir, respectively.

Oral valganciclovir hydrochloride tablets can achieve similar body ganciclovir exposure levels when administered at recommended doses of intravenous ganciclovir, which is effective in the treatment of CMV retinitis. The area under the ganciclovir curve (AUC) correlates with the time to progression of CMV retinitis.

Prevention of CMV viral infection after transplantation: A double-blind, double-dummy, active-controlled clinical trial was conducted in high-risk patients (D+/R-) with CMV infection after heart, liver, and kidney transplantation. Patients started taking Vancevir (900 mg/time/day) or ciclovir (1000 mg tid) within 10 days after transplantation until 100 days after transplantation. CMV infection as judged by the Research Efficacy Committee includes CMV syndrome and tissue-invasive infection. The incidence of CMV infection within 6 months after transplantation was 12.1% in the Vancevir group (n=239) and 15.2% in the oral ganciclovir group (n=125). Most CMV infection cases occurred later in the valganciclovir hydrochloride tablets group after stopping preventive treatment (after 100 days) than in the ganciclovir group. The incidence of acute rejection within 6 months after transplantation was 29.7% in the tablet group and 36.0% in the oral ganciclovir group (n=125).